Updated November 7, 2026 | v7.4

Renal updates by clinical finding

Search 237 product updates by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.

Search all 1,215 records | Source cautions

Restriction or avoidance

Olanzapine and samidorphan l-malate (Lybalvi), oral tablet

Renal measure: Indexed GFR/eGFR, mL/min/1.73 m2
Renal action or finding: No renal reduction is specified at eGFR 15-89 mL/min/1.73 m2. Use is not recommended below 15.
Limits and monitoring: This applies to the olanzapine/samidorphan combination. Review opioid-related contraindications separately.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 16, posted Feb 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Restriction or avoidance

Posaconazole (Noxafil), IV injection only

Renal measure: Indexed GFR/eGFR, mL/min/1.73 m2
Renal action or finding: Avoid IV posaconazole when eGFR is below 50 mL/min/1.73 m2 unless the anticipated benefit outweighs the risk of vehicle accumulation. Follow serum creatinine closely.
Limits and monitoring: Oral products have different formulation-specific instructions. If creatinine rises, assess switching to an appropriate oral formulation.

Review 1 product or source caution

Vehicle accumulation is specific to the IV formulation. Do not apply this threshold to oral products.

DailyMed SPL version 56, posted Mar 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Restriction or avoidance

Rivaroxaban (Xarelto), adult oral DVT/PE treatment

Renal measure: Creatinine clearance (CrCl), mL/min
Renal action or finding: For adult DVT/PE treatment, avoid rivaroxaban if CrCl is below 15 mL/min. At 15 to below 30, evidence is limited and bleeding warrants close evaluation.
Limits and monitoring: Use the table for the specific indication. The AF, CAD/PAD and pediatric instructions have different eligibility and dosing assumptions.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 65, posted Sep 11, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Restriction or avoidance

Sumatriptan succinate and naproxen sodium (Treximet), oral tablet

Renal measure: Creatinine clearance (CrCl), mL/min
Renal action or finding: Avoid routine use of the sumatriptan/naproxen combination at CrCl below 30 mL/min.
Limits and monitoring: Assess kidney function and the NSAID-related risk. This restriction applies to the fixed product.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 8, posted Dec 26, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Restriction or avoidance

Tolvaptan (Samsca), oral tablet

Renal measure: Creatinine clearance (CrCl), mL/min
Renal action or finding: CrCl below 10 mL/min is an unstudied range in which tolvaptan's sodium effect is likely lost. The label recommends against use there.
Limits and monitoring: Anuria is a contraindication. Apply the hyponatremia product's hospital initiation and sodium-monitoring instructions.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 23, posted Jun 01, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Restriction or avoidance

Voclosporin (Lupkynis), oral capsule

Renal measure: Indexed GFR/eGFR, mL/min/1.73 m2
Renal action or finding: If baseline eGFR is 45 mL/min/1.73 m2 or lower, voclosporin is not recommended unless the expected benefit outweighs the risk.
Limits and monitoring: Check the label's lower starting regimen if used in severe impairment and its eGFR monitoring and adjustment algorithm.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 12, posted Aug 27, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

RX coverage and remaining workload | Previous 90-product roundup